Te Xiao Qian Lie Kang No.1

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

Polygonum aviculare, Quantity: 26 mg; Cinnamomum cassia, Quantity: 56 mg (Equivalent: coumarin, Qty 6 microgram; Equivalent: Cassia Oil, Qty 16 microgram); Glycyrrhiza uralensis, Quantity: 19 mg; Polyporus umbellatus, Quantity: 26 mg; Alpinia oxyphylla, Quantity: 22 mg; Cyathula officinalis, Quantity: 84 mg; Citrus reticulata, Quantity: 124 mg (Equivalent: oxedrine, Qty 0 mg); Pyrrosia sheareri, Quantity: 23 mg; Pinus massoniana, Quantity: 39 mg; Sinapis alba, Quantity: 26 mg (Equivalent: allyl isothiocyanate, Qty 13 microgram); Plantago asiatica, Quantity: 55 mg

Available from:

Wai Shun Pty Ltd

INN (International Name):

Alpinia oxyphylla,Cinnamomum cassia,Citrus reticulata,Cyathula officinalis,Glycyrrhiza uralensis,Pinus massoniana,Plantago asiat

Pharmaceutical form:

Capsule, hard

Composition:

Excipient Ingredients: Gelatin

Administration route:

Oral

Class:

Medicine Listed

Therapeutic indications:

Helps reduce occurrence of medically diagnosed cystitis ; Helps decrease/reduce/relieve burning sensation/irritation upon urination associated with medically diagnosed cystitis

Product summary:

Visual Identification: ;

Authorization status:

Listed

Authorization date:

2006-09-27

Summary of Product characteristics

Version: pfpvinci10921
Supersedes: pfpvinci10321
Page 1 of 16
AUSTRALIAN
PRODUCT
INFORMATION
–
VINCRISTINE SULFATE INJECTION
1.
NAME OF THE MEDICINE
Vincristine sulfate
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Vincristine Sulfate Injection contains 1 mg/mL of vincristine sulfate.
For the full list of excipients, see Section 6.1 List of excipients.
3.
PHARMACEUTICAL FORM
Solution for injection.
Vincristine Sulfate Injection is a sterile, hypertonic,
preservative-free solution.
4.
CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Vincristine is used primarily in the treatment of acute leukaemia,
usually as a component of
various chemotherapeutic regimens. It has also been used as part of
combination therapy in the
treatment of Hodgkin’s disease, non-Hodgkin’s malignant lymphomas,
rhabdomyosarcoma,
neuroblastoma, Wilm’s tumour, osteogenic sarcoma, mycosis fungoides,
Ewing’s sarcoma,
carcinoma of the uterine cervix, breast cancer, malignant melanoma,
oat-cell carcinoma of the
lung and gynaecological tumours of childhood.
Vincristine may be useful in patients with true idiopathic
thrombocytopenic purpura resistant
to the usual treatment, but is not recommended as primary treatment
for this disorder.
4.2 DOSE AND METHOD OF ADMINISTRATION
This preparation is for intravenous use only and is usually
administered at weekly intervals. It
can be fatal if administered intrathecally (see sections 4.3
Contraindications and 4.4 Special
warnings and precautions for use).
Vincristine should not be given intramuscularly, subcutaneously or
intrathecally. Intrathecal
use of vincristine usually results in death. When dispensed, flexible
plastic containers
containing this product should be labelled:
FOR INTRAVENOUS USE ONLY. FATAL IF
GIVEN BY ANY OTHER ROUTE.
Version: pfpvinci10921
Supersedes: pfpvinci10321
Page 2 of 16
DOSAGE
Neurotoxicity appears to be dose related. Extreme care must be used in
calculating and
administrating the dose of vincristine since overdosage may have very
serious or fatal outcome
(see section 4.9 O